19:06:03 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


Calmark är verksamma inom medicinteknik. Bolaget specialiserar sig inom utveckling av diagnostik riktade mot nyfödda barn. Tekniken utgår ifrån den egenutvecklade plattformen och används för analys de första veckorna efter födseln. Instrumentet används som biomarkör för att studera blodvärden. Bolaget grundades under 2007 och har sitt huvudkontor i Karlstad.


2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-27 Kvartalsrapport 2021-Q2
2021-05-28 Kvartalsrapport 2021-Q1
2021-05-19 Ordinarie utdelning CALMA B 0.00 SEK
2021-05-18 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-12-23 Extra Bolagsstämma 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-20 Kvartalsrapport 2020-Q1
2020-05-15 Ordinarie utdelning CALMA B 0.00 SEK
2020-05-14 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-25 Kvartalsrapport 2019-Q3
2019-11-06 Extra Bolagsstämma 2019
2019-08-27 Kvartalsrapport 2019-Q2
2019-05-23 Kvartalsrapport 2019-Q1
2019-05-10 Ordinarie utdelning CALMA B 0.00 SEK
2019-05-09 Årsstämma 2019
2019-02-28 Bokslutskommuniké 2018
2018-11-26 Kvartalsrapport 2018-Q3
2018-08-27 Kvartalsrapport 2018-Q2
2021-06-10 18:59:49

Calmark Sweden AB (publ) has entered an exclusive distributor agreement with the company r2 Hemostasis Diagnostics India Private Ltd regarding marketing and sales of the Calmark POC - Covid platform in the Indian market. 

Since March, India has reported a dramatic surge in infections, peaking at approximately 400,000 confirmed new COVID-19 cases per day in early May. The prevailing situation is putting a heavy strain on the healthcare system, which in many places is struggling to meet the need for hosppital beds, equipment and pharmaceuticals. Calmark POC - Covid is a platform for rapid testing of the LDH biomarker, which is an important factor in the assessment of the level of care that will be needed for each patient.

The company r2 Hemostasis Diagnostics India Private Ltd is an expert in coagulation and is active throughout India and in neighbouring countries. The reputable company also operates in other areas, including pharma and life sciences research.

"I am delighted and very, very pleased with today's agreement," says Magdalena Tharaldsen, Director International Business Development at Calmark. "Our product will now be registered in India, a process which will be managed by r2 Hemostasis Diagnostics. We will send over the first product sampes shortly."

Calmark POC - Covid is a platform consisting of an instrument and a test cassette for measurement of the lactate dehydrogenase (LDH) biomarker in the blood of COVID-19 patients. Elevated levels of LDH are associated with a higher risk of severe disease and death in COVID-19 patients. The platform can be used in, e.g., emergency rooms and hospital wards to assess the required level of care.


Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.

This disclosure contains information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 10-06-2021 19:00 CET.